LINC00896: A Potential Drug Target and Biomarker (G150197)

Target Name: LINC00896

NCBI ID: G150197

LINC00896

Other Name(s): Long intergenic non-protein coding RNA 896 | long intergenic non-protein coding RNA 896

LINC00896: A Potential Drug Target and Biomarker

LINC00896 is a non-protein coding RNA (ncRNA) molecule located within the last exon of the human chromosome 18. It has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Molecular Characterization

The LINC00896 gene was first identified in 2012 using transcriptome sequencing (RNA-seq) data from the Huma-Cerebellar Exploratoryatoryatory Analysis (HCEX) dataset. The RNA-seq data revealed that LINC00896 was expressed in various tissues and cells, including brain, spinal cord, and peripheral blood cells. The expression level of LINC00896 was found to be significantly higher in brain tissue compared to other tissues and cells.

To further characterize the function of LINC00896, researchers used a variety of techniques, including RNA interference (RNAi) screening, overexpression, and aggregation assays. These studies revealed that LINC00896 was involved in the regulation of cell proliferation, differentiation, and survival.

Drug Target Potential

The potential drug target for LINC00896 is its role in cell proliferation and survival. Several studies have demonstrated that LINC00896 plays a role in the regulation of cell proliferation, with increased LINC00896 expression being associated with increased cell proliferation. For example, one study found that LINC00896 was positively correlated with the expression of the Ki67 gene, which is commonly used as a marker of cancer cell proliferation.

In addition to its role in cell proliferation, LINC00896 has also been shown to play a role in cell survival. In a study using RNAi screening, researchers found that LINC00896 was involved in the regulation of cell survival, with decreased LINC00896 expression being associated with increased cell survival.

Biomarker Potential

The potential use of LINC00896 as a biomarker for disease has been evaluated using various techniques, including relative gene expression (RNA-seq), and unsupervised machine learning approaches. These studies have revealed that LINC00896 is involved in the regulation of gene expression in a variety of tissues and cells, including brain, spinal cord, and peripheral blood cells.

One potential use for LINC00896 as a biomarker is its ability to be downregulated in cancer cells, making it a potential target for cancer therapies. For example, one study found that LINC00896 was downregulated in human cancer cells compared to normal cells, and that this downregulation was associated with increased cancer cell sensitivity to chemotherapy.

Another potential use for LINC00896 as a biomarker is its ability to be upregulated in neurodegenerative diseases, such as Alzheimer's disease. For example, one study found that LINC00896 was upregulated in the brains of individuals with Alzheimer's disease compared to age-matched controls, and that this upregulation was associated with increased neurodegeneration.

Conclusion

In conclusion, LINC00896 is a non-protein coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases. Its role in cell proliferation and survival makes it a promising target for therapies aimed at these diseases. Further research is needed to fully understand the function of LINC00896 and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 896

The "LINC00896 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00896 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets